Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) ... 2015 of $226.5 million, down 6%.  Excluding currency ... The Company reported a fourth quarter GAAP net ... Adjusted net income, exclusive of transformation, restructuring and ... up 1%, and adjusted earnings per share were ...
(Date:4/27/2015)... and HEIDELBERG , ... Addresses unmet need in treatment of millions ... it has been granted a patent in ... latest patent supports Molecular Health,s discovery that EPHB4 is a ... and promotes tumor growth. EPO stimulates the production of red ...
(Date:4/27/2015)... DryLet, LLC a biotechnology company ... as animal waste reduction, bioremediation, wastewater treatment, aquaculture ... treatment plants and restaurant kitchen settings, announced today ... Commission on Environmental Quality (TCEQ) Environmental Trade Fair ... The company will highlight three of its key ...
Breaking Biology Technology:SynGen Inc. Expands Its Management Team 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 31Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2
... Wisconsin technology leaders hit the road , ,MILWAUKEE - ... small business is and you will get one answer: SALES. ... most neglected discipline in business school curricula today. What They ... event held by the Kellogg Alumni Club of Chicago titled ...
... merger with another new life science organization, and is ... information systems that supported the operations of both companies. ... are facing new challenges they did not encounter within ... best practices, and experiences, at different levels, is becoming ...
... , ,Madison, WI - WE Energies announced Monday ... that will build three wind farms increasing the total ... , ,Under the agreement, the two developers, Navitas Energy, ... in Chicago, will provide their entire energy output from ...
Cached Biology Technology:Sales Strategies for the High-Tech Entrepreneur 2Sales Strategies for the High-Tech Entrepreneur 3Sales Strategies for the High-Tech Entrepreneur 4Sales Strategies for the High-Tech Entrepreneur 5Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies 2Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies 3Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies 4WE Energies Is Not Letting Wind Power Blow Away 2
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... release is available in German . ... in micro- and nanotechnologies for users from science and ... is starting operation: Ten leading institutions from research and ... total of 36 high-tech installations along with the corresponding ...
... the U.S. from Europe and other places, garlic mustard first ... indicates that eventually, however, its primary weapon a fungus-killing ... The study, in Proceedings of the National Academy of ... evolutionary forces can alter the very attributes that give an ...
... CORVALLIS, Ore. Research in the Linus Pauling Institute at ... previously have been studied for their ability to prevent cancer, ... treating it working side-by-side with the conventional drugs that ... published in the International Journal of Cancer examined ...
Cached Biology News:Scientific pathways into the nanoworld 2Scientific pathways into the nanoworld 3Over time, an invasive plant loses its toxic edge 2Over time, an invasive plant loses its toxic edge 3Natural compounds, chemotherapeutic drugs may become partners in cancer therapy 2Natural compounds, chemotherapeutic drugs may become partners in cancer therapy 3
... The micro 1 is a dramatic breakthrough in ... 1mL with 10nL resolution, the micro 1 has ... dispenser. And, the micro 1 never needs re-calibration ... Touch Screen programming on an LCD Display , ...
... series embodies all aspects of classical microscopy ... powerful Achromatic Super Contrast (ASC) objectives coupled ... this microscope combines flexibility and professional microscopy ... B1 series, the DM-B1 steps into the ...
... to Rad51 ( Abpromise for ... Antigen: Synthetic peptide: VEEESFGPQPISRLE conjugated ... amino acids 15-29 of Human Rad51 ... 5888 Swiss ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: